Lucid Diagnostics gets Nasdaq notice over low stock price
Nasdaq told Lucid Diagnostics on October 12, 2026 that its stock has traded below $1 for 30 straight business days, triggering a compliance deadline.
Lucid Diagnostics Inc. disclosed in an 8-K that on October 12, 2026 it received a letter from Nasdaq's Listing Qualifications Department. The letter stated that for the prior 30 consecutive business days, through October 9, 2026, the closing bid price of the company's common stock had stayed under the $1 per share threshold required to remain listed on the Nasdaq Capital Market under Listing Rule 5550(a)(2).1
Nasdaq gave the company a window to fix the problem. The letter said Lucid has 180 calendar days, until April 12, 2027, to regain compliance, which requires the closing bid price to reach at least $1 for ten consecutive business days.1 If that deadline passes without compliance, there may be a second chance. The letter noted that if the company fails to regain compliance within the first 180 days, it could qualify for an additional 180-day period.1 But if Lucid does not qualify for that extension, or if Nasdaq staff conclude the deficiency cannot be cured, the Listing Qualifications Department will issue a delisting notice after the initial period ends.1
For now, trading is unaffected. The notice does not currently change the listing status of Lucid's common stock, which keeps trading under the ticker "LUCD."1 The company said it intends to weigh all available options for regaining compliance with Nasdaq's listing standards.1
The filing was signed by Chief Financial Officer Dennis McGrath and dated October 16, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.